Skip to main content
Midas Edge

Atara Biotherapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

ATRA$8.10-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Stock · ​ · Paid-in · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
For the Nine Months Ended September 30, 2026 · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Income (Loss) · ​ ​ ​ · Deficit · ​ ​ ​ · Equity (Deficit)
Balance as of January 1, 2026​7,324​$1​$1,983,361​$1​$(2,021,865)​​(38,502)
Issuance of pre-funded warrants in connection with HCRx Amendment​—​​—​​1,672​​—​​—​​1,672
Issuance of common stock through ATM facilities, net of commissions and offering costs of $82​493​​—​​2,915​​—​​—​​2,915
Exercise of pre-funded warrants​630​​—​​—​​—​​—​​—
RSU settlements, net of shares withheld​65​​—​​—​​—​​—​​—
Stock-based compensation expense​—​​—​​749​​—​​—​​749
Net (loss) income​—​​—​​—​​—​​(4,145)​​(4,145)
Unrealized gain (loss) on available-for-sale securities​—​​—​​—​​(1)​​—​​(1)
Balance as of March 31, 2026​8,512​$1​$1,988,697​$-​$(2,026,010)​$(37,312)
Issuance of common stock through ATM facilities, net of commissions & offering cost of $145​498​​—​​4,758​​—​​—​​4,758
Stock-based compensation expense​—​​—​​394​​—​​—​​394
Exercise of pre-funded warrants​362​​—​​—​​—​​—​​—
RSU settlements, net of shares withheld​71​​—​​—​​—​​—​​—
Net (loss) income​—​​—​​—​​—​​(4,834)​​(4,834)
Unrealized gain (loss) on available-for-sale securities​—​​—​​—​​(2)​​—​​(2)
Balance as of June 30, 2026​9,443​$1​$1,993,849​$(2)​$(2,030,844)​$(36,996)
Issuance of common stock in ATM, net of commissions and offering costs of $134​104​​—​​865​​—​​—​​865
RSU settlements, net of shares withheld​46​​—​​—​​—​​—​​—
Exercise of pre-funded warrants​595​​—​​—​​—​​—​​—
Stock-based compensation expense​—​​—​​457​​—​​—​​457
Net (loss) income​—​​—​​—​​—​​(2,229)​​(2,229)
Unrealized gain (loss) on available-for-sale securities​—​​—​​—​​1​​—​​1
Balance as of September 30, 2026​10,188​$1​$1,995,171​$(1)​$(2,033,073)​$(37,902)
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Stock · ​ · Paid-in · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
For the Nine Months Ended September 30, 2025 · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Income (Loss) · ​ ​ ​ · Deficit · ​ ​ ​ · Equity (Deficit)
Balance as of January 1, 2025​5,859​$1​$1,957,261​$8​$(2,054,553)​$(97,283)
RSU settlements, net of shares withheld​65​​—​​—​​—​​—​​—
Stock-based compensation expense​—​​—​​4,209​​—​​—​​4,209
Net (loss) income​—​​—​​—​​—​​38,010​​38,010
Unrealized gain (loss) on available-for-sale securities​—​​—​​—​​(8)​​—​​(8)
Balance as of March 31, 2025​5,924​$1​$1,961,470​$—​$(2,016,543)​$(55,072)
Issuance of pre-funded warrants to purchase common stock through an underwritten registered direct offering, net of offering costs of $522​834​​—​​14,843​​—​​—​​14,843
RSU settlements, net of shares withheld​220​​—​​(1)​​—​​—​​(1)
Issuance of common stock pursuant to employee stock awards​—​​—​​1​​—​​—​​1
Stock-based compensation expense​—​​—​​2,801​​—​​—​​2,801
Net (loss) income​—​​—​​—​​—​​2,387​​2,387
Balance as of June 30, 2025​6,978​$1​$1,979,114​$—​$(2,014,156)​$(35,041)
Issuance of common stock through ATM facilities, net of commissions and offering costs of $48​125​​—​​1,471​​—​​—​​1,471
RSU settlements, net of shares withheld​106​​—​​—​​—​​—​​—
Issuance of common stock pursuant to employee stock awards​1​​—​​12​​—​​—​​12
Stock-based compensation expense​—​​—​​1,225​​—​​—​​1,225
Net (loss) income​—​​—​​—​​—​​(4,303)​​(4,303)
Unrealized gain (loss) on available-for-sale securities​—​​—​​—​​2​​—​​2
Balance as of September 30, 2025​7,210​$1​$1,981,822​$2​$(2,018,459)​$(36,634)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.